Canadian pilot trial of haplo-identical donor transplantation  by Walker, I et al.
were transplanted with unmanipulated bone marrow and 10 pa-
tients received peripheral blood stem cells either from HLA iden-
tical related (n 44) or unrelated (n 26) or partially mismatched
donor (n  12). Relapse rate was low 16% (13/82) and overall
survival was 52% at a median follow up of 4 years. Risk category
based on the International Prognostic Scoring System (IPSS) at the
time of transplant and median survival respectively was: low (n 
14, median not reached), intermediate-1 (n  39, 110 months),
intermediate-2 (n  19, 27 months) and high (n  10, median not
reached). Predictors evaluated were age, time from diagnosis to
transplant, bone marrow blasts, cytogenetics, risk scoring (IPSS),
FAB classiﬁcation at the time of transplantation and bone marrow
cellularity. Age was not signiﬁcantly associated with other predic-
tors. In univariate analysis, bone marrow blasts, FAB classiﬁcation
and cytogenetics were weakly associated with overall survival. Risk
scoring (IPSS) had same predictive value for survival as bone
marrow blasts and cytogenetics in univariate analysis. In multiva-
riable model, all the predictors had little predictive ability for
survival. Given the low relapse rates in our study, it is not surpris-
ing that there was even less predictive ability in multivariate model
for relapse. In conclusion, a substantial number of patients in all
the risk categories achieved long-term disease free survival. Risk
stratiﬁcation at the time of allogenic transplantation may not pre-
dict the long-term survival and this curative treatment should be
offered to patients in all the risk categories.
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CANADIAN PILOT TRIAL OF HAPLO-IDENTICAL DONOR TRANSPLAN-
TATION
Walker, I.1, Cantin, G.2, Couture, F.2, Dhe´din, N.3, Barty, R.1, Foley,
R.1, Sutherland, R.4, Schultz, K.5 1. McMaster University, Hamilton,
ON, Canada; 2. Universite´ Laval, Quebec City, QC, Canada; 3. Uni-
versite´ de Montre´al, Montreal, QC, Canada; 4. University of Toronto,
Toronto, ON, Canada; 5. University of British Columbia, Vancouver,
BC, Canada; 6. Canadian Blood and Marrow Transplant Group, Van-
couver, BC, Canada.
Background: CBMTG multi-centre pilot study of haplo-iden-
tical donor BMT. AIMS: To assess 1. Ability to collect suitable
graft (CD34  5 x 106/kg and CD3 1 x 105/kg recipient body
weight), 2. Toxicity, 3. Survival to day 100. Eligibility: All
diagnoses and ages; accrual to end after 20 patients with AML in
remission and age less than 55 years. Methods: Preparation: Mod-
iﬁed Perugia regimen, chemotherapy alone; melphalan 140 mg/m2
d -9, thiotepa 10 mg/kg day -7, ﬂudarabine 40 mg/m2 days -7 to -3,
and ATG (Thymoglobulin, Sangstat) days -6 to -2 (total 10.5
mg/kg). Infection prophylaxis: Ganciclovir (GC) 5 mg/kg days
5-20 then x5/week until day100 then x3/week until 210 (subjects
1-3), foscarnet (FC)90 mg/kg days 4-21 then short course pre-
emptive GC or FC (subjects 4-11); ﬂuconazole; cotrimoxazole.
Donors: G-CSF 16 g/kg daily x 5 until second pheresis day.
T-cell depletion: CliniMACS (MiltenyiBiotec). RESULTS:
Eleven (11) patients with AML have been transplanted from 4
centres, 8 female, 3 male, mean age 39 (range 19-60). Disease
status, ﬁrst CR 1/11, second CR 4/11, third CR1/11 , relapse 5/11.
Graft CD34 5 x 106/kg was achieved in all cases, median 13.72
x 106/kg (Q1, Q3: 8.92, 16.61; min 5.59, max 22.2), and CD3 was
1 x 105/kg in all cases, median of 0.49 x104/kg (Q1, Q3: 0.33,
1.64; min 0.22, max 4.10). Ten (10) of the 11 patients have died,
median survival 109 days (Q1, Q3: 67, 153; min 0, max  841).
Survival to day 100 6/11 (55%). Four (4) patients died of leuke-
mic relapse, 6 of infection. Of 6 patients dying of infection, CMV
was a deﬁnite cause in 4. Of 4 dying with relapse, CMV was
signiﬁcant in 1 and asymptomatic in another. Engraftment was
assessed in 10 patients who survived0 days. Granulocyte engraft-
ment (0.5 x 109/L) achieved in all patients, median 12 days (Q1,
Q3: 11, 16; min 8, max 70). Platelet engraftment (20 x 109/L)
achieved in 8 of 10 patients, median of 18 days (Q1, Q3: 14, 37;
min 9, max 97). The two platelet non-engrafters died on days 45
and 61. Toxicity was low, with one toxic death (day 0), and the
Bearman organ toxicity gradings were  grade 2 in all other
patients. Conclusions: Haplo-identical transplantation is feasible,
with a high engraftment rate, minimal toxicity and minimal risk of
graft versus host disease and rejection. However, relapse and CMV
infection were frequent complications in this ultra-high risk group
of patients. Physicians have been reluctant to refer earlier.
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SECOND HEMATOPOIETIC STEM CELL TRANSPLANT USING UNRE-
LATED DONOR UMBILICAL CORD BLOOD CURES 50% OF PEDIATRIC
PATIENTS WITH LEUKEMIA RELAPSING AFTER PRIOR ALLOGENEIC
TRANSPLANT FROM A MATCHED RELATED SIBLING
Staba, S.L., Szabolcs, P., Driscoll, T., Martin, P.L., Kurtzberg, J. Duke
University Medical Center, Durham, NC.
Leukemic relapse after allogeneic stem cell transplant is difﬁcult
to treat and carries a poor prognosis. Cytotoxic therapy has limited
efﬁcacy and subsequent myeloablative transplants are associated
with signiﬁcant treatment related toxicity. We report results of 4
children who relapsed after matched related donor bone marrow
transplants (BMT) and then underwent unrelated donor umbilical
cord blood transplantation (UCBT) following conditioning with
Fludarabine/Melphalan/ATG. Between 7/00 and 5/03 4 children
who experienced leukemic relapse after 1 (n  3) or 2 (n  1)
matched sibling transplants underwent UCBT at Duke University
Medical Center. The average age at the time of UCBT was 7 1/3
years (range 5 1⁄2 to 15 1⁄2 years) old with a median weight of 26 kg
(range 20-45 kg). The median time from initial BMT to UCBT
was 13 months. Two children had ALL (high risk Pre-B ALL
(BMT in CR2, UCBT in CR3); Philadelphia chromosome positive
ALL (BMT in CR 1, DLI in CR2, UCBT in CBR3)) and two had
AML (M1 AML (BMT in CR1 and CR2, UCBT in relapse); M2
AML (BMT in CR2, DLI x 4 in CR3, UCBT in relapse)). All
patients had previously received TBI and were prepared for UCBT
with Fludarabine 25mg/m2 qd x 5, Melphalan 45mg/m2 qd x 3 and
ATG. Cyclosporine and intermediate dose steroids were given for
GVHD prophylaxis. Three children received a 4/6 HLA matched
UCB unit, one a 3/6 HLA matched unit, all with at least one
mismatch at DRB1. The median nucleated cell dose was 9.8 x
107cells/kg (range 5.6–14.4 x 107cells/kg). All 4 demonstrated
complete donor engraftment (absolute neutrophil count greater
than 500/L for three consecutive days) at a median of 24 (range
10–27) days post transplant. Platelet engraftment (untransfused
platelet count 50,000/uL) occurred at a median of 55 days post
transplant. One patient developed acute GVHD (grade 1 skin) and
there was no chronic GVHD seen. The event free survival and
overall survival are both 50%. One child died in remission of
Legionella pneumonia on day96 post transplant, and one died of
relapse on day  424 after UCBT. Two of the 4 patients are
surviving disease free for a median of 775 (range 362-1189) days
post transplant. UCBT after cytoreduction with ﬂudarabine/mel-
phalan/ATG is a viable option as a treatment for leukemic relapse
after matched related allogeneic transplant, with low GVHD rate,
tolerable treatment related mortality and 50% event free survival.
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SIROLIMUS AND TACROLIMUS ALLOW ENGRAFTMENT OF HAPLOIDEN-
TICAL AND OTHER ALTERNATIVE DONOR STEM CELLS AFTER NON-
MYELOABLATIVE CONDITIONING
Claxton, D.F.1, Popescu, D.1, Carraher, M.1, Chiafari, F.A.2, Ehmann,
C.1, Rybka, W.1 1. Penn State Milton S Hershey Medical Center,
Hershey, PA; 2. BRT Laboratories, Baltimore, MD.
Sirolimus (Rapamycin) was added to an established non-myeloa-
blative regimen in order to examine its effects on engraftment and
GVHD. Between 5/2001 and 7/2003 32 patients with advanced
hematological malignancies received alternative donor hematopoi-
etic cell transplantation. Ages ranged from 22-72 (median 62), and
prior therapies from 1-6 (median 3). All received cyclophospha-
mide 1 gram/M2 days -7 and -6, and ﬂudarabine 25 mg/M2 days
-7 through -3 (5 doses). Sirolimus began on day -7 and tacrolimus
on day -4, with methotrexate 5 mg/M2 days 1, 3, and 6 after stem
cell infusion. Graft sources included haploidentical related donors
(3 or 4/6 antigen matched-haplo)-11 cases, 5/6 matched related
donors-8 cases, matched unrelated donors (URD) 12 cases, and in
one case cord blood. Patients receiving haplo stem cells also re-
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